Med Page Today
OCTOBER 29, 2024
(MedPage Today) -- The heparin frequently given before percutaneous coronary intervention (PCI) should be pushed to as early as possible in patients with ST-segment elevation myocardial infarction (STEMI), according to findings from the Chinese.
Medical Xpress - Cardiology
OCTOBER 29, 2024
Until now, patients with aortic stenosis—a narrowing of one of the heart's main valves—have had to wait until symptoms become severe before undergoing valve replacement. Findings from the EVOLVED study, however, indicate that patients can avoid symptoms such as chest pain, dizziness and fainting if surgery is performed at an earlier stage of the condition.
Med Page Today
OCTOBER 29, 2024
(MedPage Today) -- SAN DIEGO -- Semaglutide (Wegovy) reduced albuminuria in patients with overweight or obesity and chronic kidney disease (CKD) but without type 2 diabetes, a randomized trial showed. Among 101 patients, those who received 2.
American College of Cardiology
OCTOBER 29, 2024
The goal of the CLEAR SYNERGY OASIS 9 trial was to determine the long-term cardiovascular (CV) effects of colchicine following percutaneous coronary intervention (PCI) for ST-segment elevation or large non–ST-segment elevation myocardial infarction (STEMI or NSTEMI, respectively).
Med Page Today
OCTOBER 29, 2024
(MedPage Today) -- A Chinese study suggested that cold weather may make people more susceptible to myocardial infarction with non-obstructive coronary arteries compared with myocardial infarction from obstructive disease. (European Heart Journal.
Becker's Hospital Review - Cardiology
OCTOBER 29, 2024
Yale New Haven (Conn.) Health and the Yale School of Medicine have appointed Marc Pelletier, MD, division chief of cardiac surgery for the department of surgery and section chief of cardiac surgery at Yale New Haven Hospital as well as physician-in-chief of cardiac surgery for the health system's Heart and Vascular Center.
HCPLive
OCTOBER 29, 2024
A study revealed using language models as diagnostic aids did not significantly enhance clinical reasoning or accuracy among physicians over conventional resources alone.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
HCPLive
OCTOBER 29, 2024
This discussion with Murina covers several tips for dermatologists to implement, 1 of which touched on omega-3 supplementation for ocular rosacea.
Cardiovascular Diabetology
OCTOBER 29, 2024
Type 2 diabetes has traditionally been a risk factor for worse prognosis after myocardial infarction (MI), but major advances have been made in its treatment, and the use of secondary preventive measures has i.
HCPLive
OCTOBER 29, 2024
A trio of stakeholders join Lungcast to discuss the ongoing, long-term assessment into the patterns and drivers of chronic lung disease in a real-world cohort.
Dr. S. Venkatesan MD
OCTOBER 29, 2024
This study was released in NEJM without much fanfare at the fag end of the last century, (rather the millennium) in 1999. Dr. Bertram Pitt and his team scripted this from the Department of Medicine, University of Michigan School of Medicine, Ann Arbor, USA. One can’t expect even in your dreams a study like this would be be done in the future. This study tested PTCA vs with a single lipid lowering drug in terms of plaque regression.
HCPLive
OCTOBER 29, 2024
At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.
DAIC
OCTOBER 29, 2024
tim.hodson Tue, 10/29/2024 - 09:55 Oct. 28, 2024 – Elixir Medical today announced late-breaking data demonstrating significant benefit of the DynamX Coronary Bioadaptor System compared to contemporary Resolute Onyx zotarolimus drug-eluting stent (DES) for target lesion failure (TLF) in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
HCPLive
OCTOBER 29, 2024
Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.
DAIC
OCTOBER 29, 2024
tim.hodson Tue, 10/29/2024 - 11:29 Impella ECP pump insertion. Oct. 28, 2024 — Results from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial flow pump with compressible pump architecture were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference in Washington, D.C. Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and a global leader in heart recovery.
Med Page Today
OCTOBER 29, 2024
(MedPage Today) -- SAN DIEGO -- Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During a median 2 years of post.
DAIC
OCTOBER 29, 2024
tim.hodson Tue, 10/29/2024 - 09:55 Oct. 28, 2024 – Elixir Medical today announced late-breaking data demonstrating significant benefit of the DynamX Coronary Bioadaptor System compared to contemporary Resolute Onyx zotarolimus drug-eluting stent (DES) for target lesion failure (TLF) in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
American College of Cardiology
OCTOBER 29, 2024
Both acute and long-term colchicine use to treat patients with acute myocardial infarction (MI) did not reduce cardiovascular death, myocardial infarction, stroke or ischemia-driven revascularization.
DAIC
OCTOBER 29, 2024
tim.hodson Tue, 10/29/2024 - 10:14 Oct. 27, 2024 — Investigators from Gifu Heart Center and Fukuoka Sanno Hospital recently presented the results of the physician-initiated PROVISION 1 Study at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C. The investigators shared the first randomized controlled trial (RCT) of FFRangio outcomes compared to invasive wire-based fractional flow reserve (FFR) has met its primary endpoi
American College of Cardiology
OCTOBER 29, 2024
In this interview, Drs. Allen Taylor and Derek Chew discuss the findings of the RAPIDxAI trial: re-engineering the clinical approach to suspected cardiac chest pain assessment in the emergency department by expediting evidence to practice using AI.
HCPLive
OCTOBER 29, 2024
Only about 2% of eligible patients with ALD have received a pharmacotherapy for alcohol use disorder—and the prescription takes more than a year to receive.
American College of Cardiology
OCTOBER 29, 2024
What is the ability of a systolic blood pressure (SBP) polygenic risk score (PRS) to predict antihypertensive treatment (AHT) response and apparent treatment-resistant hypertension (aTRH)?
HCPLive
OCTOBER 29, 2024
Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.
Becker's Hospital Review - Cardiology
OCTOBER 29, 2024
"Discover how addressing women's heart health could lead to a $28 billion annual growth in the U.S. economy by 2040.
HCPLive
OCTOBER 29, 2024
Iyer describes differences between short bowel syndrome and intestinal failure and explains the value of GLP-2 analogs like apraglutide for treatment.
American College of Cardiology
OCTOBER 29, 2024
While the main PROTECTED TAVR trial found no significant differences in stroke rates when cerebral embolic protection (CEP) was used during TAVR compared with TAVR alone, a post hoc analysis of the trial presented during TCT 2024 and simultaneously published in JAMA Cardiology, suggests there may be potential benefits associated with CEP use based on geographic region.
HCPLive
OCTOBER 29, 2024
Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.
American College of Cardiology
OCTOBER 29, 2024
The goal of the ECLIPSE trial was to evaluate orbital atherectomy prior to drug-eluting stent (DES) implantation compared with conventional percutaneous coronary intervention (PCI) without atherectomy among patients with calcified coronary lesions.
HCPLive
OCTOBER 29, 2024
Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.
American College of Cardiology
OCTOBER 29, 2024
Sirolimus-coated balloons were noninferior to paclitaxel-coated balloons in terms of safety and efficacy in treating patients with femoropopliteal artery disease, based on findings from the head-to-head.
HCPLive
OCTOBER 29, 2024
Complete, 24-month data from the IGNAZ study were presented at the ASN Kidney Week 2024 Meeting.
American College of Cardiology
OCTOBER 29, 2024
The routine use of orbital atherectomy did not improve minimal stent area (MSA) or reduce target vessel failure (TVF) at one year compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary lesions.
Medical Xpress - Cardiology
OCTOBER 29, 2024
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
American College of Cardiology
OCTOBER 29, 2024
In women with symptomatic, severe aortic stenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aortic valve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.
HeartRhythm
OCTOBER 29, 2024
The practice of medicine relies on noninvasive imaging modalities such as computed tomography or magnetic resonance imaging (MRI), which reconstruct noninvasively anatomy of internal organs. Electrocardiographic imaging (ECGI) performs functional imaging. It maps noninvasively the electrical function of the heart. It reconstructs electrical potentials, electrograms, activation sequences, and repolarization patterns on the epicardium.
HCPLive
OCTOBER 29, 2024
A qualitative / quantitative study shows significant gaps in PBC diagnosis confidence and skill between care providers.
American College of Cardiology
OCTOBER 29, 2024
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.
Expert insights. Personalized for you.
111 
Let's personalize your content